CINXE.COM
Fabry Disease | ASGCT - American Society of Gene & Cell Therapy |
<!DOCTYPE html> <html xmlns="http://www.w3.org/1999/xhtml"> <head> <!-- Google Tag Manager --> <script type="text/javascript">(function (w, d, s, l, i) { w[l] = w[l] || []; w[l].push({ 'gtm.start': new Date().getTime(), event: 'gtm.js' }); var f = d.getElementsByTagName(s)[0], j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f); })(window, document, 'script', 'dataLayer', 'GTM-NFW5DS9');</script> <!-- End Google Tag Manager --> <!-- Begin Informz Tracking --> <script type="text/javascript"> //------------------------------------------------------- var z_account = "2632C1D8-6432-4D3A-93D6-08AAECC53F86"; var z_collector = "asgct.informz.net"; var z_cookieDomain = ".asgct.org"; //------------------------------------------------------- (function (e, o, n, r, t, a, s) { e[t] || (e.GlobalSnowplowNamespace = e.GlobalSnowplowNamespace || [], e.GlobalSnowplowNamespace.push(t), e[t] = function () { (e[t].q = e[t].q || []).push(arguments) }, e[t].q = e[t].q || [], a = o.createElement(n), s = o.getElementsByTagName(n)[0], a.async = 1, a.src = r, s.parentNode.insertBefore(a, s)) }(window, document, "script", "https://cdn.informz.net/web_trk/sp.js", "informz_trk")), informz_trk("newTracker", "infz", z_collector + "/web_trk/collector/", { appId: z_account, cookieDomain: z_cookieDomain }), informz_trk("setUserIdFromLocation", "_zs"), informz_trk("enableActivityTracking", 30, 15); informz_trk("trackPageView", null); </script> <!-- End Informz Tracking --> <meta charset="utf-8" /> <meta http-equiv="X-UA-Compatible" content="IE=edge" /> <meta name="viewport" content="width=device-width,user-scalable=no,maximum-scale=1.0,initial-scale=1.0" /> <link href="/BlueKey/pe_assets/build/styles.css" rel="stylesheet" /> <script type="text/javascript" defer="defer" src="https://extend.vimeocdn.com/ga/127349852.js"></script> <meta name="twitter:card" content="summary_large_image" /> <meta name="twitter:site" content="https://twitter.com/ASGCTherapy" <meta name="twitter:creator" content="@ASGCTherapy" <meta name="twitter:title" content="Fabry Disease" <meta name="twitter:description" content="Fabry disease has a classic form (Type 1) that starts in childhood, and a form with late onset in adulthood (Type 2). Both types are caused by a mutated galactosidase alpha (GLA) gene and have varying levels of severity. " <meta name="twitter:image" content="~/getattachment/Disease-Treatments/Fabry/Fabry_Disease_330x230_1_00000.png.aspx" <meta name="description" content="Fabry disease is a rare genetic disorder caused by a lacking enzyme due to a faulty gene." /> <meta charset="UTF-8" /> <link href="/App_Themes/Default/Images/favicon.ico" type="image/x-icon" rel="shortcut icon" /> <link href="/App_Themes/Default/Images/favicon.ico" type="image/x-icon" rel="icon" /> <title> Fabry Disease | ASGCT - American Society of Gene & Cell Therapy | </title></head> <body class="LTR IE IE7 ENUS ContentBody"> <!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NFW5DS9" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> <form method="post" action="/disease-treatments/fabry" id="aspnetForm"> <div class="aspNetHidden"> <input type="hidden" name="__CMSCsrfToken" id="__CMSCsrfToken" value="WAEjLBBt8Sq+zz3hbO5jqEcG1xA/+/Ir4MXI5T/uLRRsa4t0cxCGTVCrz+chBhw+2xKrVzJ3dIAdv1TWvhT86s6mTPQ=" /> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="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" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['aspnetForm']; if (!theForm) { theForm = document.aspnetForm; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="/WebResource.axd?d=UZQNzmZXG1IdUaHxtavOjRvGEvOmz1kvw97PqEaxzBy7Ys-tUotw-RqgdbsvC3g_7cXjehqAdA_N6kbuK73WBAVGdxo1&t=638562384440000000" type="text/javascript"></script> <input type="hidden" name="lng" id="lng" value="en-US" /> <script type="text/javascript"> //<![CDATA[ function PM_Postback(param) { if (window.top.HideScreenLockWarningAndSync) { window.top.HideScreenLockWarningAndSync(1080); } if(window.CMSContentManager) { CMSContentManager.allowSubmit = true; }; __doPostBack('ctl00$CMSPortalManager1$am',param); } function PM_Callback(param, callback, ctx) { if (window.top.HideScreenLockWarningAndSync) { window.top.HideScreenLockWarningAndSync(1080); }if (window.CMSContentManager) { CMSContentManager.storeContentChangedStatus(); };WebForm_DoCallback('ctl00$CMSPortalManager1$am',param,callback,ctx,null,true); } //]]> </script> <script src="/ScriptResource.axd?d=WTJtoz6EJe-loUBJ9stbRxqzgpVp8oo0KdZGkhGfcu6Lr7kb5LeNfx21FKi8mxEL1oDZOLAxiAqERpClgBx-A6lZ0DJ1qKcDZB1NuIbRd8o9S7aG0&t=7c776dc1" type="text/javascript"></script> <script src="/ScriptResource.axd?d=y6KGkkRaceYF_mkApXCXMQ_rMQVX59BlJ-ut-lQDHw88bR5bbS86epdVNwimj01duE6_OophLX4sBTOgb8_5dNLaY2Mx5DHMJj7Rbr4kPMV1-AOS5VF5-QEC8oG-_-aHoWoyqA2&t=7c776dc1" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ var CMS = CMS || {}; CMS.Application = { "isDialog": false, "isDebuggingEnabled": false, "applicationUrl": "/", "isRTL": "false", "imagesUrl": "/CMSPages/GetResource.ashx?image=%5bImages.zip%5d%2f" }; //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="2CD64FB1" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAAMHHMyqqT/oHgXeBtpk2sVRDMN6QAizBz4KoPbUd79oAZD1NQdfl/cWuar5Vh7dGPRgWqZ5/AKMf0pQ8y++fMTHvYpwXQ==" /> </div> <script type="text/javascript"> //<![CDATA[ Sys.WebForms.PageRequestManager._initialize('ctl00$manScript', 'aspnetForm', ['tctl00$ctxM',''], [], [], 90, 'ctl00'); //]]> </script> <div id="ctl00_ctxM"> </div> <header class="c-header"> <a href="#content" class="show-on-focus">Skip to main content</a> <div class="c-header-utilities"> <div class="container"> <div class="columns is-vcentered"> <div class="column"> <a href="https://asgct.org" class="is-external">ASGCT.org</a> </div> <div class="column is-half"> <a href="/"> <div class="c-header-images"> <div class="c-header-image"> <img src="/PatientEducation/media/PatientEducation/ASGCT_Web_Horz_Navy.png?ext=.png" alt="" /> </div> <div class="c-header-image"> <img src="/PatientEducation/media/PatientEducation/temp-pe-logo.png?ext=.png" alt="Patient Education Logo" /> </div> </div> </a> </div> <!--/search-results?searchtext=<enteredtext>--> <div class="column"> <div class="c-header-search"> <div class="c-header-search-wrap"> <input name="keyword" type="text" id="searchtext" placeholder="Search" aria-required="false" /> <label for="searchtext" class="is-sr-only">Keyword search</label> <button type="button" data-encode="searchtext" data-path="/search-results" data-query="searchtext"> <span class="is-sr-only">Search</span> <span class="c-search-icon"></span> </button> </div> </div> </div> </div> </div> </div> <div class="c-header-utilities-mobile"> <div class="c-header-images"> <div class="c-header-image"> <a href="https://asgct.org" class="is-external"><img src="/PatientEducation/media/PatientEducation/ASGCT_Web_Horz_Navy.png?ext=.png" alt="" /></a> </div> <div class="c-header-image"> <a href="/"><img src="/PatientEducation/media/PatientEducation/temp-pe-logo.png?ext=.png" alt="Patient Education Logo" /></a> </div> </div> <button class="c-nav-toggle" type="button" aria-controls="c-nav-main" aria-expanded="false" data-togglevisibility="data-togglevisibility"> <p class="is-sr-only">Open Navigation</p> <p class="is-sr-only" aria-hidden="true">Close Navigation</p> <span class="c-nav-toggle-menu"></span> </button> </div> <div id="ctl00_plcMain_bkSiteHeader_headerBanner"> <div class="header-alert"> <div class="container"> <p id="ctl00_plcMain_bkSiteHeader_pBanner"><b><a href="https://patienteducation.asgct.org/newsletter/subscribe-to-the-patient-press">Subscribe today to ASGCT's patient-centered newsletter, The Patient Press!</a></b></p> </div> </div> </div> <nav class="c-nav-main" id="c-nav-main" aria-hidden="true"> <div class="container"> <div class="c-header-search is-hidden-desktop"> <div class="c-header-search-wrap"> <input name="" type="text" id="global-search" placeholder="Search" aria-required="false" /> <label for="global-search" class="is-sr-only">Keyword search</label> <button type="button" data-encode="global-search" data-path="/search-results" data-query="searchtext"> <span class="is-sr-only">Search</span> <span class="c-search-icon"></span> </button> </div> </div> <ul> <li> <a href="/gene-therapy-101">Gene & Cell Therapy 101</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/gene-therapy-101/gene-therapy-basics">Gene Therapy Basics</a> </li> <li> <a href="/gene-therapy-101/cell-therapy-basics">Cell Therapy Basics</a> </li> <li> <a href="/gene-therapy-101/gene-therapy-approaches">Gene Therapy Approaches</a> </li> <li> <a href="/gene-therapy-101/gene-editing">Gene Editing</a> </li> <li> <a href="/gene-therapy-101/clinical-trials">Clinical Trials</a> </li> <li> <a href="/gene-therapy-101/vectors-101">Vectors 101</a> </li> <li> <a href="/gene-therapy-101/glossary">Glossary</a> </li> <li> <a href="/gene-therapy-101/covid19-vaccines">COVID-19</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/disease-treatments">Condition Treatments</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/disease-treatments/fda-approved-cell-gene-therapy-products">FDA-Approved Cell & Gene Therapy Products</a> </li> <li> <a href="/disease-treatments/batten">Batten Disease</a> </li> <li> <a href="/disease-treatments/blood-disorders">Beta Thalassemia & Other Blood Disorders</a> </li> <li> <a href="/disease-treatments/leukodystrophy">CALD and MLD</a> </li> <li> <a href="/disease-treatments/car-t-basics">CAR-T Basics</a> </li> <li> <a href="/disease-treatments/fabry">Fabry Disease</a> </li> <li> <a href="/disease-treatments/gaucher-disease">Gaucher Disease</a> </li> <li> <a href="/disease-treatments/gm1-gangliosidosis">GM1 Gangliosidosis</a> </li> <li> <a href="/disease-treatments/gm2-tay-sachs-sandhoff">Tay-Sachs and Sandhoff Disease</a> </li> <li> <a href="/disease-treatments/hemophilia">Hemophilia</a> </li> <li> <a href="/disease-treatments/huntingtons-disease">Huntington's Disease</a> </li> <li> <a href="/disease-treatments/inherited-retinal-diseases">Inherited Retinal Diseases</a> </li> <li> <a href="/disease-treatments/mps">Mucopolysaccharidoses (MPS)</a> </li> <li> <a href="/disease-treatments/muscular-dystrophy">Muscular Dystrophy</a> </li> <li> <a href="/disease-treatments/pompe-disease">Pompe Disease</a> </li> <li> <a href="/disease-treatments/parkinsons-disease">Parkinson's Disease</a> </li> <li> <a href="/disease-treatments/sickle-cell-disease">Sickle Cell Disease</a> </li> <li> <a href="/disease-treatments/sma">Spinal Muscular Atrophy</a> </li> <li> <a href="/disease-treatments/wilson-disease">Wilson Disease</a> </li> <li> <a href="/disease-treatments/xlmtm">X-Linked Myotubular Myopathy</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/patient-journey">Patient Journey</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/patient-journey/identifying-a-genetic-disease">Identifying a Genetic Disease</a> </li> <li> <a href="/patient-journey/next-steps-with-a-diagnosis">Next Steps With a Diagnosis</a> </li> <li> <a href="/patient-journey/patient-focused-policy-positions">Patient-Focused Policy Positions</a> </li> <li> <a href="/patient-journey/stimulating-research">Stimulating Research</a> </li> <li> <a href="/patient-journey/considering-a-clinical-trial">Considering a Clinical Trial</a> </li> <li> <a href="/patient-journey/ethical-issues-germline-gene-editing">Ethical Issues: Germline Gene Editing</a> </li> <li> <a href="/patient-journey/ethical-issues-illegitimate-clinical-trials">Ethical Issues: Unproven Stem Cell Products</a> </li> <li> <a href="/patient-journey/gene-therapy-centers">Gene Therapy Centers</a> </li> <li> <a href="/patient-journey/clinical-trials-finder">Clinical Trials Finder</a> </li> <li> <a href="/patient-journey/on-demand">On Demand Webinars</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/newsletter">Newsletter</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/newsletter/subscribe-to-the-patient-press">Subscribe to The Patient Press</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/quick-takes">Quick Takes</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/quick-takes/focused-ultrasound-in-cell-and-gene-therapies">Focused Ultrasound in CGTs</a> </li> <li> <a href="/quick-takes/access-to-approved-cell-and-gene-therapies">Access to Approved CGTs</a> </li> <li> <a href="/quick-takes/informed-consent">Informed Consent</a> </li> <li> <a href="/quick-takes/state-of-the-field-cgt-highlights-and-approvals-20">State of the Field: CGT Highlights and Approvals of 2023</a> </li> <li> <a href="/quick-takes/genetic-testing-and-clinical-trial-eligibility">Genetic Testing and Clinical Trial Eligibility</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/events">Events</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/events/empowering-patients-2025-a-cell-and-gene-therapies">Empowering Patients 2025: A Cell and Gene Therapies Summit</a> </li> <li> <a href="/events/annual-meeting-patient-advocate-offerings">Annual Meeting-Patient Advocate Offerings</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/about-asgct">About</a> <button type="button"><span class="is-sr-only">toggle subnavigation</span></button> <ul> <li> <a href="/about-asgct/overview">Overview</a> </li> <li> <a href="/about-asgct/about-asgct">About ASGCT</a> </li> <li> <a href="/about-asgct/news">ASGCT News</a> </li> <li> <a href="/about-asgct/privacy-policy">Privacy Policy</a> </li> </ul> <div class="navDropToggle"></div> </li> <li> <a href="/support">Support</a> </li> </ul> <a href="asgct.org" class="px-1 is-external is-hidden-desktop">ASGCT.org</a> </div> </nav> <div class="c-banner" style="background: url('/getattachment/Disease-Treatments/Fabry/Fabry_Disease_1280x720_1_00000.png.aspx') 50%/cover no-repeat;"> <div class="c-banner-content container"> <h1>Fabry Disease</h1> </div> </div> </header> <main class="c-main" id="content"> <section class="c-breadcrumbs"> <div class="container"> <span><a href="/">Home</a> > </span> <a href="/disease-treatments" title="Condition Treatments" class="CMSBreadCrumbsLink">Condition Treatments</a> > <span class="CMSBreadCrumbsCurrentItem">Fabry Disease</span> </div> </section> <section class="section"> <div class="container"> <div class="columns"> <div class="column is-8"> <div class="c-leader"> </div> <div class="content mb-6"> <p>Fabry disease is a rare genetic disorder caused by the lack of an enzyme due to a faulty gene. Without enough of this key enzyme, a part inside cells called lysosomes are unable to do their job of breaking down waste. This results in a buildup that causes a variety of symptoms, including pain, fatigue, and kidney and/or heart failure, and can be life-threatening. Gene therapy aims to offer a one-time treatment to slow or ideally stop progression of the disease by introducing a working GLA gene to provide instructions to the cells to produce the deficient enzyme.</p> <p><iframe allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="315" src="https://www.youtube.com/embed/UqPP732iJ-8" width="560"></iframe></p> <h2>Fabry Disease and Gene Therapy</h2> <p>Fabry disease has a classic form (Type 1) that starts in childhood, and a form with late onset in adulthood (Type 2). Both types are caused by a mutated galactosidase alpha (GLA) gene and have varying levels of severity. The GLA gene provides the instructions for cells to produce the alpha-galactosidase-A (α-Gal A) enzyme, which helps the lysosomes then break down waste like fats and sugars because lysosomes are a part of cells that function as the “recycling center.”</p> <p><a href="https://asgct.org/global/documents/patient-ed-infographics/sept-launch-website-material/fabry-disease-and-gene-therapy.aspx" target="_blank"><img alt="" src="https://asgct.org/getmedia/bad29470-4da6-4ac2-a5e0-766812d61a0a/Fabry-button-for-infographic.aspx?width=350&height=350" style="width: 350px; height: 350px; float: right; margin: 5px 10px;" /></a>One gene therapy approach to deliver a working copy of the GLA gene into cells is <em>in vivo</em>. This involves an injection of the gene therapy into specific parts of the body so that new genetic instructions can be delivered directly to the cells within the body. The new instructions to the cells would be to produce α-Gal-A enzyme that will restore lysosomal function to break down the buildup of a type of fat called globotriaosylceramide (Gb3). This is done using a vector, which is like an envelope with a message, that delivers the working gene to the target cells. Vectors are often derived from viruses, since they are very good at getting into cells. However, all the viral genes are removed, and the vector is modified to only deliver therapeutic genes into cells. Gene therapy approaches currently being studied either deliver the vectors to reach the cells of the liver or target the heart along with other affected organs such as the kidneys and liver.</p> <p>There is also an <em>ex vivo</em> approach being studied for Fabry disease, meaning outside the body. This requires the use of stem cells, which are versatile cells that can develop into many different cell types depending on what the body needs. For this approach, there are specific stem cells removed from the person’s body, which are then modified by introducing a vector (carrying the working GLA gene) to these cells. The modified cells are then returned to the body to deliver the new instructions of the working GLA gene to create more of the α-Gal-A enzyme.</p> <h2>Treatment Pipeline</h2> <p>There are gene therapy approaches for Fabry disease that are currently in preclinical studies and clinical trials. Research and development of these therapies is being done by companies including 4DMT Therapeutics, Amicus, AvroBio, Sangamo and Uniqure.</p> <p>To stay up to date on active and recruiting clinical trials in the U.S. or globally, visit the <a href="https://app.emergingmed.com/asgct/home/">ASGCT Clinical Trials Finder</a> and search for Fabry disease in the "diagnosis" filter.</p> <h2>Existing Treatments</h2> <p>There is currently no cure for Fabry disease. Enzyme replacement therapy is a treatment that works well to reduce Gb3 lipids in many tissues of the body, but does not effectively reduce Gb3 in the heart’s muscle cells. This results in heart complications. Enzyme replacement therapy requires lifelong infusions, which can be required as often as every two weeks. There is also an oral treatment available, but it only works for those with certain types of GLA gene mutations.</p> <h2>Availability</h2> <p>There are ongoing gene therapy clinical trials for Fabry disease, while other research is still in preclinical studies, which are the earliest stages of research. This is a necessary <a href="/gene-therapy-102/clinical-trials-process">phase of research</a> that establishes the safety and effectiveness of a treatment in animal or cell-based models before proceeding with human clinical trial investigation. Eligibility for a trial is based on strict inclusion and exclusion criteria, which is an important way for researchers to understand if the gene therapy is working properly and to ensure participant safety. For example, some trials for Fabry disease require the individual to be 18 years or older, male, and have not received enzyme replacement therapy within the last 10 years. However, this criteria can vary and some trials allow a participant to continue enzyme replacement therapy. It is important to consult your treating physician <a href="/clinical-trials/considering-a-clinical-trial">before considering clinical trial participation.</a></p> <h2>Get Involved</h2> <p>Getting involved with patient advocacy organizations is a great way to connect with other families and people affected by Fabry disease. These organizations help provide useful resources or guidance and often advocate and raise funds for research. The diseases may be rare, but you and your family are not alone.</p> <ul> <li><a href="https://fabry.org/" target="_blank">Fabry Support & Information Group</a></li> <li><a href="https://www.fabrydisease.org/" target="_blank">National Fabry Disease Foundation</a></li> <li><a href="http://www.fabrynetwork.org/" target="_blank">Fabry International Network</a></li> </ul> </div> </div> <div class="column is-4 pl-4"> <div class="c-nav-local-wrap"> <div class="asideBox"> <h3> Related Pages</h3> <hr class="is-secondary" /> <ul class="c-nav-local-list"> <li class="c-nav-local-item"><a class="c-nav-local-link" href="/disease-treatments/fda-approved-cell-gene-therapy-products">FDA-Approved Cell & Gene Therapy Products</a> </li> <li class="c-nav-local-item"><a class="c-nav-local-link" href="/disease-treatments/gaucher-disease">Gaucher Disease</a> </li> </ul> </div> </div> </div> </div> </div> <div class="lastUpdatedTag"> <p>Last Updated: 01/22/2021</p> </div> </section> </main> <footer class="c-footer"> <div class="c-footer-primary"> <section class="section"> <div class="container"> <div class="columns"> <div class="column c-footer-section"> <p><img alt="" src="/PatientEducation/media/PatientEducation/logo_white.png" /></p> <p>20800 Swenson Dr., Suite 300<br /> Waukesha, WI 53186</p> </div> <div class="column is-two-fifths c-footer-section"> <ul class="c-utility-list"> <li><a href="#">Gene Therapy 101</a></li> <li><a href="#">Disease Treatments</a></li> <li><a href="#">Clinical Trials</a></li> <li><a href="/patient-journey">Patient Journey</a></li> <li><a href="/about-asgct">About</a></li> <li><a href="/support">Support</a></li> <li><a href="https://asgct.org/about/privacy-policy" target="_blank">Privacy Policy</a></li> </ul> </div> <div class="column c-footer-section"> <h3 class="mb-3">Connect with ASGCT</h3> <p class="mb-0"><span>Phone: 414</span>.278.1341</p> <p><a href="mailto:info@asgct.org">info@asgct.org</a></p> <p> <div class="c-social"> <ul class="c-social-list"> <li class="c-social-item"><a href="https://twitter.com/ASGCTherapy" target="_blank" class="c-social-link twitter"><span class="is-sr-only">Twitter</span></a></li> <li class="c-social-item"><a href="https://www.facebook.com/ASGCTherapy" target="_blank" class="c-social-link facebook"><span class="is-sr-only">Facebook</span></a></li> <li class="c-social-item"><a href="https://www.instagram.com/asgctherapy" target="_blank" class="c-social-link instagram"><span class="is-sr-only">Instagram</span></a></li> <li class="c-social-item"><a href="https://www.linkedin.com/company/asgct" target="_blank" class="c-social-link linkedin"><span class="is-sr-only">LinkedIn</span></a></li> <li class="c-social-item"><a href="https://www.youtube.com/user/ASGCT" target="_blank" class="c-social-link youtube"><span class="is-sr-only">YouTube</span></a></li> </ul> </div> </p> </div> </div> </div> </section> </div> <div class="c-footer-secondary"> <section class="section py-4"> <div class="container"> <div class="columns"> <div class="column"> <p class="is-small">© 2024 All rights reserved. American Society of Gene & Cell Therapy.</p> <p class="is-tiny">Web design by <a href="https://www.reasononeinc.com/kentico" target="_blank">Reason One</a>. Powered by <a href="http://www.kentico.com" target="_blank">Kentico</a>.</p> </div> </div> </div> </section> </div> </footer> <div class="CookieConsent"> <span id="ctl00_cookieLawQ_lblText" class="ConsentText">This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.</span> <span class="ConsentButtons"> <input type="submit" name="ctl00$cookieLawQ$btnAllowSpecific" value="OPT OUT" id="ctl00_cookieLawQ_btnAllowSpecific" class="ConsentButton btn btn-default" /> <input type="submit" name="ctl00$cookieLawQ$btnAllowAll" value="ACCEPT" id="ctl00_cookieLawQ_btnAllowAll" class="ConsentButton btn btn-default" /> </span> </div> <script src="/BlueKey/pe_assets/build/main.js" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ var callBackFrameUrl='/WebResource.axd?d=nNME_ObE2oIDm535eYM9xWmIMy-HXBVdo54Ly6sA5tAYPS1aA-gFDzodlP9ijTBRgmjStONrH4-ISuRTp7slHiYkACw1&t=638562384440000000'; WebForm_InitCallback();//]]> </script> </form> </body> </html>